Novo Nordisk Overpriced: Shift to High-Yield Drug Stocks

↑
↑

  //stocks-investing.news-articles.net/content/202 .. -overpriced-shift-to-high-yield-drug-stocks.html
  Published in Stocks and Investing on Monday, December 22nd 2025 at 4:08 GMT by The Motley Fool

Forget Novo Nordisk, Buy High‑Yield Drug Stocks

On December 22, 2025 the Motley Fool posted an article that challenges the prevailing hype around Novo Nordisk. The piece argues that the Danish diabetes‑treating giant has become over‑priced and that investors would be better served by shifting their capital into high‑yield drug makers such as Gilead Sciences, Biogen, and a handful of other peers. Below is a detailed, 500‑plus‑word summary of the article’s key points, supporting data, and the context it provides for making a portfolio shift.

1. The Premise: Novo Nordisk Is “Too Big” – and Too Expensive

The article opens with a quick look at Novo Nordisk’s market performance over the past year. While the company has indeed delivered impressive revenue growth from its flagship GLP‑1 drugs (Ozempic, Wegovy), the stock’s valuation multiples have outpaced the broader pharmaceutical sector. Key take‑aways include:

The author stresses that a P/E of 43x, driven by lofty expectations for next‑generation diabetes treatments, signals a price that may not be sustainable. Even if Novo continues to grow, the implied earnings‑growth rates are hard to justify when compared to the sector average.

The article also highlights the company’s heavy concentration in the diabetes segment, meaning its revenue is tightly coupled to a single therapeutic area. In contrast, the high‑yield peers are more diversified across oncology, immunology, and neurology.

2. Why “High‑Yield” Matters

The Motley Fool piece frames “high‑yield” in two ways:

1. Dividend Yield – A measure of cash returned to shareholders, which is especially appealing in a low‑interest‑rate environment.
2. Earnings Yield – The inverse of the P/E ratio, which is a quick gauge of how many dollars in earnings you’re paying for each dollar of share price.

The article cites that many high‑yield pharma names deliver earnings yields in the 5–6% range—substantially higher than Novo’s ~3.4%. The implied price‑earnings ratio for these peers is 18–20x, a more conservative valuation that still offers a respectable upside.

3. The “High‑Yield” Candidates

Gilead Sciences (GILD)
- Dividend yield: 4.3%
- Earnings yield: 6.1% (≈ 16x forward P/E)
- Strong pipeline in antiviral and oncology products; recently acquired a promising CAR‑T therapy, adding a new revenue stream.

Biogen (BIIB)
- Dividend yield: 2.5%
- Earnings yield: 5.5% (≈ 18x forward P/E)
- Focus on neurodegenerative diseases; the company has recently secured FDA approval for a new ALS drug, raising prospects for long‑term growth.

Amgen (AMGN)
- Dividend yield: 3.8%
- Earnings yield: 5.9% (≈ 17x forward P/E)
- Broad portfolio in oncology and rare diseases; has recently announced a partnership with a biotech that could accelerate drug development.

Johnson & Johnson (JNJ)
- Dividend yield: 2.9%
- Earnings yield: 5.2% (≈ 19x forward P/E)
- Though a conglomerate, its pharmaceutical arm brings in stable revenue from immunology and infectious diseases.

These stocks not only offer superior dividend yields but also carry the advantage of diversified pipelines, reducing reliance on a single therapeutic niche.

4. Risks and Caveats

The author is careful to outline the main risks associated with the high‑yield approach:

• Patent Expirations: Many of these companies face upcoming patent cliffs that could erode revenue streams.
• Regulatory Scrutiny: High‑yield stocks like Gilead and Biogen are often under intense FDA review, making earnings less predictable.
• Valuation Concerns: Even though the earnings yields are attractive now, market sentiment could shift, tightening the multiples again.
• Interest‑Rate Impact: While dividends are a plus, rising rates may compress their present value.

The article recommends that investors use a “margin‑of‑safety” approach—only buying when the dividend yield and earnings yield exceed a certain threshold and the company’s pipeline is robust.

5. Practical Steps to Rebalance

1. Sell a Portion of Novo Shares – The article suggests selling 20–30% of a Novo position to free up capital for high‑yield names.
2. Reallocate into a Diversified ETF – A pharma ETF that focuses on high‑yield stocks (e.g., the Invesco S&P 500® Health Care ETF, XLV) can spread risk.
3. Direct Purchase of GILD, BIIB, AMGN, JNJ – If the investor prefers individual names, the recommended allocation is 25% each.
4. Monitor Regulatory Updates – Set up alerts for FDA decisions that could affect earnings.

6. Bottom Line

The Motley Fool article presents a compelling argument that Novo Nordisk, while still a growth story, is becoming a “growth‑capped” investment. In a low‑interest‑rate world where investors are looking for cash flow and stability, high‑yield drug stocks provide a balanced mix of income and upside. By shifting a modest portion of a Novo portfolio into the likes of Gilead, Biogen, Amgen, and J&J, investors can potentially capture higher earnings yields without sacrificing too much upside.

Author’s Note: This summary reflects the viewpoints expressed in the article. As always, individual investors should conduct their own due diligence and consider how these recommendations fit into their overall risk tolerance and investment objectives.